96 results on '"Grayson, Peter C."'
Search Results
2. Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study.
- Author
-
Karadag, Omer, Bolek, Ertugrul Cagri, Ayan, Gizem, Mohammad, Aladdin J., Grayson, Peter C., Pagnoux, Christian, Martín‐Nares, Eduardo, Monti, Sara, Abe, Yoshiyuki, Alberici, Federico, Alibaz‐Oner, Fatma, Cuthbertson, David, Dagna, Lorenzo, Direskeneli, Haner, Khalidi, Nader A., Koening, Curry, Langford, Carol A., McAlear, Carol A., Monach, Paul A., and Moroni, Luca
- Subjects
PROTEINURIA ,SURVIVAL rate ,INTERPROFESSIONAL relations ,CREATININE ,RESEARCH funding ,SCIENTIFIC observation ,SYMPTOMS ,DESCRIPTIVE statistics ,AGE distribution ,CENTRAL nervous system ,RETROSPECTIVE studies ,WORLD health ,LONGITUDINAL method ,MEDICAL records ,ACQUISITION of data ,SOCIODEMOGRAPHIC factors ,POLYARTERITIS nodosa ,GASTROINTESTINAL diseases - Abstract
Objective: We describe the demographics, clinical features, disease course, and survival of polyarteritis nodosa (PAN) through an international collaboration (GLOBAL‐PAN). Methods: Patients with PAN were recruited between 1990 and 2020 from observational cohorts of nine countries across Europe, Japan, and North America. Eligibility was retrospectively defined using the European Medicines Agency classification algorithm. Patients with PAN related to hepatitis B virus (n = 12) and two monogenic diseases mimicking PAN, deficiency of adenosine deaminase 2 enzyme (n = 16) or familial Mediterranean fever (n = 11), were excluded. Data regarding organ involvement, relapse, disease‐related damage, and survival were analyzed. Results: Three hundred fifty‐eight patients (female:male ratio 174:184), including those with systemic PAN (sPAN, n = 282) and cutaneous PAN (n = 76), were included. Twenty‐five were pediatric onset. Mean ± SD age at diagnosis was 44.3 ± 18.1 years. Constitutional symptoms (71.5%), cutaneous involvement (70.5%), musculoskeletal findings (69.1%), and neurologic features (48.0%) were common manifestations. Among patients with sPAN, gastrointestinal involvement and proteinuria over 400 mg/day were reported in 52.2% and 11.2%, respectively. During a median (interquartile range) 59.6 (99.5) months of follow‐up, relapse occurred in 48.5% of patients. One, 5‐ and 10‐year survival rates for sPAN were 97.1%, 94.0%, and 89.0%, respectively. Predictors of death for sPAN included age ≥65 years at diagnosis, serum creatinine at diagnosis >140 μmol/L, gastrointestinal manifestations, and central nervous system (CNS) involvement. Conclusion: The spectrum of PAN remains a complex, multifaceted disease. Relapse is common. Age ≥65 years and serum creatinine >140 μmol/L at diagnosis, as well as gastrointestinal and CNS involvement, are independent predictors of death in sPAN. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. VEXAS‐Defining UBA1 Somatic Variants in 245,368 Diverse Individuals in the NIH All Of Us Cohort.
- Author
-
Corty, Robert W., Brogan, James, Byram, Kevin, Springer, Jason, Grayson, Peter C., and Bick, Alexander G.
- Subjects
AFRICAN Americans ,SEX distribution ,ENZYMES ,AUTOINFLAMMATORY diseases ,AGE distribution ,DISEASE prevalence ,LONGITUDINAL method ,BIOINFORMATICS ,GENETIC mutation ,COMPARATIVE studies ,PHENOTYPES ,SEQUENCE analysis ,ALLELES - Abstract
Objective: Somatic variants in UBA1 cause VEXAS, a recently described, systemic autoinflammatory disease. Research on VEXAS has largely focused on highly symptomatic patients. We sought to determine the prevalence of canonical, VEXAS‐associated somatic variants and their disease penetrance in a diverse, unselected population. Methods: We analyzed clinical‐grade whole genome sequencing data from 245,368 participants in the All of Us Research Program. We compared persons carrying a canonical VEXAS‐associated somatic variant to age, sex, and ancestry matched controls across the domains of diagnoses, medications, and laboratory values. Results: 74 participants were identified who carry one VEXAS‐defining somatic variant, UBA1 c.121A>C, p.Met41Leu. The variant allele fraction ranged from 4.5% to 33%. No other canonical VEXAS‐associated variants were identified. Of the 74 carriers, 62 (84%) were women, 20 (27%) were African American, and 14 (19%) were American Admixed/Latino. There was no statistically significant association between case/control status and any VEXAS‐associated diagnosis code, medication prescription, or laboratory value. Conclusion: We report the largest cohort to date of persons with the VEXAS‐associated p.Met41Leu somatic variant. This cohort differed substantially from reported cohorts of patients with clinical VEXAS, having a higher proportion of persons who were young, female, and of diverse ancestry. Variant allele fractions were lower than reported in clinical VEXAS cohorts, and bioinformatic analysis detected no clinical manifestations of VEXAS. Thus, the UBA1 p.Met41Leu somatic variant displayed incomplete penetrance for VEXAS. Further study is needed to determine the natural history of VEXAS‐associated somatic variants in the predisease phase. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Development of the Takayasu Arteritis Integrated Disease Activity Index.
- Author
-
Marvisi, Chiara, Bolek, Ertugrul Cagri, Ahlman, Mark A., Alessi, Hugh, Redmond, Christopher, Muratore, Francesco, Galli, Elena, Ricordi, Caterina, Kaymaz‐Tahra, Sema, Ozguven, Salih, Alibaz‐Oner, Fatma, Direskeneli, Haner, Salvarani, Carlo, Quinn, Kaitlin A., and Grayson, Peter C.
- Subjects
ACUTE phase proteins ,LITERATURE reviews ,TUMOR necrosis factors ,TAKAYASU arteritis ,RANDOMIZED controlled trials ,TEST validity - Abstract
Objective: Accurate clinical assessment of disease activity in Takayasu arteritis (TAK) can be challenging. 18F‐fluorodeoxyglucose–positron emission tomography (FDG‐PET) can directly measure vascular inflammation. This study details the development of a new type of disease activity index called the Takayasu's Arteritis Integrated Disease Activity Index (TAIDAI). Methods: Clinical symptoms for TAIDAI were identified from a literature review. Each symptom was paired with FDG‐PET findings in corresponding arterial territories. Constitutional symptoms were paired with acute phase reactant levels. One point was given for each clinical symptom paired with supporting FDG‐PET or laboratory abnormalities and summed into the TAIDAI score. A TAIDAI of ≥1 defined active disease. To assess performance of TAIDAI, face validity, content validity, and sensitivity to change were evaluated within a prospective observational cohort study of patients with TAK. Results: Seventeen clinical symptoms were paired with imaging or laboratory abnormalities. In a cohort of 96 patients contributing 204 study visits, TAIDAI showed excellent sensitivity (96.3%) and good specificity (79.2%) compared to physician's clinical assessment. TAIDAI significantly correlated with physician global assessment, PET Vascular Activity Score, patient global assessment, and acute phase reactant levels. In patients treated with either tumor necrosis factor inhibitors or tocilizumab, a TAIDAI of 0 was achieved in 21 (91%) of 23 patients who met a predefined definition of clinical response. Conclusion: TAIDAI is new type of disease activity index in TAK in which clinical symptoms are integrated with specific laboratory and imaging findings. TAIDAI should be validated in future randomized controlled trials in TAK. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu's arteritis, ANCA-associated vasculitis and giant cell arteritis.
- Author
-
Gutierrez-Rodrigues, Fernanda, Wells, Kristina V., Jones, Adrianna I., Hironaka, Dalton, Rankin, Cameron, Gadina, Massimo, Sikora, Keith A., Alemu, Lemlem, Calado, Rodrigo T., Quinn, Kaitlin A., Patel, Bhavisha, Young, Neal S., and Grayson, Peter C.
- Published
- 2024
- Full Text
- View/download PDF
6. Ultra-rare genetic variation in relapsing polychondritis: a whole-exome sequencing study.
- Author
-
Yiming Luo, Ferrada, Marcela A., Sikora, Keith A., Rankin, Cameron, Alessi, Hugh D., Kastner, Daniel L., Zuoming Deng, Mengqi Zhang, Merkel, Peter A., Kraus, Virginia B., Allen, Andrew S., and Grayson, Peter C.
- Published
- 2024
- Full Text
- View/download PDF
7. Longitudinal Characterization of Vascular Inflammation and Disease Activity in Takayasu Arteritis and Giant Cell Arteritis: A Single‐Center Prospective Study.
- Author
-
Alessi, Hugh D., Quinn, Kaitlin A., Ahlman, Mark A., Novakovich, Elaine, Saboury, Babak, Luo, Yiming, and Grayson, Peter C.
- Subjects
VASCULAR diseases ,POSITRON emission tomography ,DISEASE duration ,DISEASE progression ,MANN Whitney U Test ,TAKAYASU arteritis ,GIANT cell arteritis - Abstract
Objective: To examine and compare disease activity over time in giant cell arteritis (GCA) and Takayasu arteritis (TAK) using multimodal assessment combining clinical, laboratory, and imaging‐based testing. Methods: Patients with GCA or TAK were enrolled into a single‐center prospective, observational cohort at any point in the disease course. Patients underwent standardized assessment, including 18F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) at enrollment and follow‐up visits. Each FDG‐PET finding was subjectively interpreted as active or inactive vasculitis. Global arterial FDG uptake was quantified by the PET Vascular Activity Score (PETVAS). Patients were stratified by disease duration at enrollment (0–2 years; 2–5 years; >5 years). Fisher exact and Mann‐Whitney U tests, Spearman's correlation, and linear regression were used for statistical analyses. Results: A total of 126 patients with large vessel vasculitis (GCA = 50; TAK = 76) were evaluated across 319 visits. Clinical disease activity was present in 33% of patients in the second to fifth year of disease and in 24% of patients evaluated >5 years after diagnosis. Active vasculitis by PET was observed in 66% of patients in years 2 to 5 after diagnosis and in 50% of patients enrolled >5 years into disease. PETVASs were consistently higher in GCA than TAK in the early and later phases of disease and significantly decreased over time in GCA but not TAK. Correlations between clinical, laboratory, and imaging findings were complex and varied with disease duration. Conclusion: Disease activity in GCA and TAK is common throughout the disease course. Patterns of vascular PET activity at diagnosis and later in disease differ between GCA and TAK. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing.
- Author
-
Ortiz-Fernández, Lourdes, Carmona, Elio G., Kerick, Martin, Lyons, Paul, Carmona, Francisco David, Mejías, Raquel López, Khor, Chiea Chuen, Grayson, Peter C., Tombetti, Enrico, Jiang, Lindi, Direskeneli, Haner, Saruhan-Direskeneli, Guher, Callejas-Rubio, José-Luis, Vaglio, Augusto, Salvarani, Carlo, Hernández-Rodríguez, Jose, Cid, Maria Cinta, Morgan, Ann W., Merkel, Peter A., and Burgner, David
- Published
- 2023
- Full Text
- View/download PDF
9. Reply.
- Author
-
Ponte, Cristina, Grayson, Peter C., Gribbons, Katherine Bates, Robson, Joanna C., Suppiah, Ravi, Judge, Andrew, Watts, Richard A., Luqmani, Raashid A., and Merkel, Peter A.
- Subjects
NURSES' associations ,GIANT cell arteritis diagnosis ,AGE distribution ,RHEUMATOLOGY ,GIANT cell arteritis ,TAKAYASU arteritis ,PHENOTYPES - Published
- 2023
- Full Text
- View/download PDF
10. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population.
- Author
-
Beck, David B., Bodian, Dale L., Shah, Vandan, Mirshahi, Uyenlinh L., Kim, Jung, Ding, Yi, Magaziner, Samuel J., Strande, Natasha T., Cantor, Anna, Haley, Jeremy S., Cook, Adam, Hill, Wesley, Schwartz, Alan L., Grayson, Peter C., Ferrada, Marcela A., Kastner, Daniel L., Carey, David J., and Stewart, Douglas R.
- Subjects
SYMPTOMS ,ELECTRONIC health records ,BLOOD diseases ,SYNDROMES ,OLDER men ,COMPLEX regional pain syndromes - Abstract
Key Points: Question: What is the prevalence, penetrance, and expressivity of UBA1 variants in a health care system cohort? Findings: In this retrospective observational study of 163 096 participants, 11 individuals (1 in 13 591) harbored a UBA1 disease-causing variant and all participants had hematologic features along with a broad spectrum of autoimmune, pulmonary, and dermatologic clinical manifestations. Meaning: This study provides an estimate of the prevalence and a description of the clinical manifestations of VEXAS (vacuoles, E1-ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic) syndrome, although additional studies are needed in unselected and genetically diverse populations to better define general population prevalence and phenotypic spectrum. Importance: VEXAS (vacuoles, E1-ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic) syndrome is a disease with rheumatologic and hematologic features caused by somatic variants in UBA1. Pathogenic variants are associated with a broad spectrum of clinical manifestations. Knowledge of prevalence, penetrance, and clinical characteristics of this disease have been limited by ascertainment biases based on known phenotypes. Objective: To determine the prevalence of pathogenic variants in UBA1 and associated clinical manifestations in an unselected population using a genomic ascertainment approach. Design, Setting, and Participants: This retrospective observational study evaluated UBA1 variants in exome data from 163 096 participants within the Geisinger MyCode Community Health Initiative. Clinical phenotypes were determined from Geisinger electronic health record data from January 1, 1996, to January 1, 2022. Exposures: Exome sequencing was performed. Main Outcomes and Measures: Outcome measures included prevalence of somatic UBA1 variation; presence of rheumatologic, hematologic, pulmonary, dermatologic, and other findings in individuals with somatic UBA1 variation on review of the electronic health record; review of laboratory data; bone marrow biopsy pathology analysis; and in vitro enzymatic assays. Results: In 163 096 participants (mean age, 52.8 years; 94% White; 61% women), 11 individuals harbored likely somatic variants at known pathogenic UBA1 positions, with 11 of 11 (100%) having clinical manifestations consistent with VEXAS syndrome (9 male, 2 female). A total of 5 of 11 individuals (45%) did not meet criteria for rheumatologic and/or hematologic diagnoses previously associated with VEXAS syndrome; however, all individuals had anemia (hemoglobin: mean, 7.8 g/dL; median, 7.5 g/dL), which was mostly macrocytic (10/11 [91%]) with concomitant thrombocytopenia (10/11 [91%]). Among the 11 patients identified, there was a pathogenic variant in 1 male participant prior to onset of VEXAS-related signs or symptoms and 2 female participants had disease with heterozygous variants. A previously unreported UBA1 variant (c.1861A>T; p.Ser621Cys) was found in a symptomatic patient, with in vitro data supporting a catalytic defect and pathogenicity. Together, disease-causing UBA1 variants were found in 1 in 13 591 unrelated individuals (95% CI, 1:7775-1:23 758), 1 in 4269 men older than 50 years (95% CI, 1:2319-1:7859), and 1 in 26 238 women older than 50 years (95% CI, 1:7196-1:147 669). Conclusions and Relevance: This study provides an estimate of the prevalence and a description of the clinical manifestations of UBA1 variants associated with VEXAS syndrome within a single regional health system in the US. Additional studies are needed in unselected and genetically diverse populations to better define general population prevalence and phenotypic spectrum. This retrospective observational study evaluates UBA1 variants in exome data from individuals in the Geisinger MyCode Community Health Initiative. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Association of 18F‐Fluorodeoxyglucose–Positron Emission Tomography Activity With Angiographic Progression of Disease in Large Vessel Vasculitis.
- Author
-
Quinn, Kaitlin A., Ahlman, Mark A., Alessi, Hugh D., LaValley, Michael P., Neogi, Tuhina, Marko, Jamie, Novakovich, Elaine, and Grayson, Peter C.
- Subjects
DISEASE progression ,MAGNETIC resonance angiography ,PATIENT aftercare ,GIANT cell arteritis ,TAKAYASU arteritis ,COMPARATIVE studies ,RADIOPHARMACEUTICALS ,POSITRON emission tomography ,DESCRIPTIVE statistics ,DEOXY sugars ,VASCULITIS ,LONGITUDINAL method - Abstract
Objective: To assess whether vascular activity seen on 18F‐fluorodeoxyglucose–positron emission tomography (FDG‐PET) scan is associated with angiographic change in large vessel vasculitis (LVV). Methods: Patients with LVV were recruited into a prospective cohort. All patients underwent magnetic resonance angiography or computed tomography angiography and FDG‐PET imaging. Follow‐up imaging using the same imaging modalities was obtained ≥6 months later per a standardized imaging protocol. Arterial damage, defined as stenosis, occlusion, or aneurysm, and corresponding FDG uptake were evaluated in 17 arterial territories. On follow‐up, development of new lesions was recorded, and existing lesions were characterized as improved, worsened, or unchanged. Results: A total of 1,091 arterial territories from 70 patients with LVV (38 patients with Takayasu arteritis, 32 patients with giant cell arteritis) were evaluated. Over a median 1.6 years of follow‐up, new lesions developed only in 8 arterial territories in 5 patients with Takayasu arteritis. Arterial lesions improved in 16 territories and worsened in 6 territories. Most arterial territories that did not have vascular activity on FDG‐PET scan at baseline had no angiographic change over the follow‐up period (787 [99%] of 793). Few territories with baseline FDG‐PET activity had angiographic change over time (24 [8%] of 298), but of the territories that developed angiographic change, 80% had FDG‐PET activity at baseline. Within the same patient, an arterial territory with baseline FDG‐PET activity had significantly increased risk for angiographic change compared to a paired arterial territory without FDG‐PET activity (odds ratio 19.49 [95% confidence interval 2.44–156.02]; P < 0.01). Concomitant edema and wall thickening further increased risk for angiographic change. Conclusion: Development of angiographic change was infrequent in this cohort of patients with LVV. A lack of baseline FDG‐PET activity was strongly associated with stable angiographic disease. In cases of angiographic progression, change was preceded by the presence of FDG‐PET activity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism.
- Author
-
Moura, Marta Casal, Zuoming Deng, Brooks, Stephen R., Wei Tew, Fervenza, Fernando C., Kallenberg, Cees G. M., Langford, Carol A., Merkel, Peter A., Monach, Paul A., Seo, Philip, Spiera, Robert F., St Clair, E. William, Stone, John H., Prunotto, Marco, Grayson, Peter C., and Specks, Ulrich
- Published
- 2023
- Full Text
- View/download PDF
13. 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis.
- Author
-
Grayson, Peter C., Ponte, Cristina, Suppiah, Ravi, Robson, Joanna C., Bates Gribbons, Katherine, Judge, Andrew, Craven, Anthea, Khalid, Sara, Hutchings, Andrew, Danda, Debashish, Luqmani, Raashid A., Watts, Richard A., Merkel, Peter A., Gribbons, Katherine Bates, and DCVAS Study Group
- Subjects
CAROTID artery ,LONGITUDINAL method ,TAKAYASU arteritis ,RHEUMATOLOGY ,INTERMITTENT claudication - Abstract
Objective: To develop and validate new classification criteria for Takayasu arteritis (TAK).Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in six phases: (1) identification of candidate criteria items, (2) collection of candidate items present at diagnosis, (3) expert panel review of cases, (4) data-driven reduction of candidate items, (5) derivation of a points-based classification score in a development data set and (6) validation in an independent data set.Results: The development data set consisted of 316 cases of TAK and 323 comparators. The validation data set consisted of an additional 146 cases of TAK and 127 comparators. Age ≤60 years at diagnosis and imaging evidence of large-vessel vasculitis were absolute requirements to classify a patient as having TAK. The final criteria items and weights were as follows: female sex (+1), angina (+2), limb claudication (+2), arterial bruit (+2), reduced upper extremity pulse (+2), reduced pulse or tenderness of a carotid artery (+2), blood pressure difference between arms of ≥20 mm Hg (+1), number of affected arterial territories (+1 to +3), paired artery involvement (+1) and abdominal aorta plus renal or mesenteric involvement (+3). A patient could be classified as having TAK with a cumulative score of ≥5 points. When these criteria were tested in the validation data set, the model area under the curve was 0.97 (95% CI 0.94 to 0.99) with a sensitivity of 93.8% (95% CI 88.6% to 97.1%) and specificity of 99.2% (95% CI 96.7% to 100.0%).Conclusion: The 2022 American College of Rheumatology/EULAR classification criteria for TAK are now validated for use in research. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
14. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis.
- Author
-
Ponte, Cristina, Grayson, Peter C., Robson, Joanna C., Suppiah, Ravi, Bates Gribbons, Katherine, Judge, Andrew, Craven, Anthea, Khalid, Sara, Hutchings, Andrew, Watts, Richard A., Merkel, Peter A., Luqmani, Raashid A., Gribbons, Katherine Bates, and DCVAS Study Group
- Subjects
BIOPSY ,GIANT cell arteritis ,BLOOD sedimentation ,LONGITUDINAL method ,RHEUMATOLOGY ,TEMPORAL arteries - Abstract
Objective: To develop and validate updated classification criteria for giant cell arteritis (GCA).Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in six phases: (1) identification of candidate items, (2) prospective collection of candidate items present at the time of diagnosis, (3) expert panel review of cases, (4) data-driven reduction of candidate items, (5) derivation of a points-based risk classification score in a development data set and (6) validation in an independent data set.Results: The development data set consisted of 518 cases of GCA and 536 comparators. The validation data set consisted of 238 cases of GCA and 213 comparators. Age ≥50 years at diagnosis was an absolute requirement for classification. The final criteria items and weights were as follows: positive temporal artery biopsy or temporal artery halo sign on ultrasound (+5); erythrocyte sedimentation rate ≥50 mm/hour or C reactive protein ≥10 mg/L (+3); sudden visual loss (+3); morning stiffness in shoulders or neck, jaw or tongue claudication, new temporal headache, scalp tenderness, temporal artery abnormality on vascular examination, bilateral axillary involvement on imaging and fluorodeoxyglucose-positron emission tomography activity throughout the aorta (+2 each). A patient could be classified as having GCA with a cumulative score of ≥6 points. When these criteria were tested in the validation data set, the model area under the curve was 0.91 (95% CI 0.88 to 0.94) with a sensitivity of 87.0% (95% CI 82.0% to 91.0%) and specificity of 94.8% (95% CI 91.0% to 97.4%).Conclusion: The 2022 American College of Rheumatology/EULAR GCA classification criteria are now validated for use in clinical research. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
15. 2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis.
- Author
-
Ponte, Cristina, Grayson, Peter C., Robson, Joanna C., Suppiah, Ravi, Gribbons, Katherine Bates, Judge, Andrew, Craven, Anthea, Khalid, Sara, Hutchings, Andrew, Watts, Richard A., Merkel, Peter A., Luqmani, Raashid A., Gatenby, Paul, Hill, Catherine, Ranganathan, Dwarakanathan, Kronbichler, Andreas, Blockmans, Daniel, Barra, Lillian, Carette, Simon, and Pagnoux, Christian
- Subjects
TEMPORAL arteries ,C-reactive protein ,RESEARCH evaluation ,BIOPSY ,CONFIDENCE intervals ,RESEARCH methodology ,GIANT cell arteritis ,SEVERITY of illness index ,BLOOD sedimentation - Abstract
Objective: To develop and validate updated classification criteria for giant cell arteritis (GCA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 6 phases: 1) identification of candidate items, 2) prospective collection of candidate items present at the time of diagnosis, 3) expert panel review of cases, 4) data‐driven reduction of candidate items, 5) derivation of a points‐based risk classification score in a development data set, and 6) validation in an independent data set. Results: The development data set consisted of 518 cases of GCA and 536 comparators. The validation data set consisted of 238 cases of GCA and 213 comparators. Age ≥50 years at diagnosis was an absolute requirement for classification. The final criteria items and weights were as follows: positive temporal artery biopsy or temporal artery halo sign on ultrasound (+5); erythrocyte sedimentation rate ≥50 mm/hour or C‐reactive protein ≥10 mg/liter (+3); sudden visual loss (+3); morning stiffness in shoulders or neck, jaw or tongue claudication, new temporal headache, scalp tenderness, temporal artery abnormality on vascular examination, bilateral axillary involvement on imaging, and fluorodeoxyglucose–positron emission tomography activity throughout the aorta (+2 each). A patient could be classified as having GCA with a cumulative score of ≥6 points. When these criteria were tested in the validation data set, the model area under the curve was 0.91 (95% confidence interval [95% CI] 0.88–0.94) with a sensitivity of 87.0% (95% CI 82.0–91.0%) and specificity of 94.8% (95% CI 91.0–97.4%). Conclusion: The 2022 American College of Rheumatology/EULAR GCA classification criteria are now validated for use in clinical research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. 2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis.
- Author
-
Grayson, Peter C., Ponte, Cristina, Suppiah, Ravi, Robson, Joanna C., Gribbons, Katherine Bates, Judge, Andrew, Craven, Anthea, Khalid, Sara, Hutchings, Andrew, Danda, Debashish, Luqmani, Raashid A., Watts, Richard A., Merkel, Peter A., Gatenby, Paul, Hill, Catherine, Ranganathan, Dwarakanathan, Kronbichler, Andreas, Blockmans, Daniel, Barra, Lillian, and Carette, Simon
- Subjects
BLOOD pressure ,CONFIDENCE intervals ,RHEUMATOLOGY ,AGE distribution ,ANGINA pectoris ,TAKAYASU arteritis ,DIAGNOSTIC imaging ,SEX distribution ,DESCRIPTIVE statistics ,SENSITIVITY & specificity (Statistics) ,VASCULITIS ,INTERMITTENT claudication ,PULSE (Heart beat) - Abstract
Objective: To develop and validate new classification criteria for Takayasu arteritis (TAK). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 6 phases: 1) identification of candidate criteria items, 2) collection of candidate items present at diagnosis, 3) expert panel review of cases, 4) data‐driven reduction of candidate items, 5) derivation of a points‐based classification score in a development data set, and 6) validation in an independent data set. Results: The development data set consisted of 316 cases of TAK and 323 comparators. The validation data set consisted of an additional 146 cases of TAK and 127 comparators. Age ≤60 years at diagnosis and imaging evidence of large‐vessel vasculitis were absolute requirements to classify a patient as having TAK. The final criteria items and weights were as follows: female sex (+1), angina (+2), limb claudication (+2), arterial bruit (+2), reduced upper extremity pulse (+2), reduced pulse or tenderness of a carotid artery (+2), blood pressure difference between arms of ≥20 mm Hg (+1), number of affected arterial territories (+1 to +3), paired artery involvement (+1), and abdominal aorta plus renal or mesenteric involvement (+3). A patient could be classified as having TAK with a cumulative score of ≥5 points. When these criteria were tested in the validation data set, the model area under the curve was 0.97 (95% confidence interval [95% CI] 0.94–0.99) with a sensitivity of 93.8% (95% CI 88.6–97.1%) and specificity of 99.2% (95% CI 96.7–100.0%). Conclusion: The 2022 American College of Rheumatology/EULAR classification criteria for TAK are now validated for use in research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. VEXAS Syndrome and Disease Taxonomy in Rheumatology.
- Author
-
Grayson, Peter C., Beck, David B., Ferrada, Marcela A., Nigrovic, Peter A., and Kastner, Daniel L.
- Subjects
X-linked genetic disorders ,RHEUMATOLOGY ,AUTOINFLAMMATORY diseases ,SYMPTOMS - Abstract
The article offers information about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome and disease taxonomy in rheumatology. It mentions that VEXAS syndrome, discovered through the use of a genotype-first approach, whereby a large genetic database was analyzed for commonalities among patients, with minimal consideration of clinical phenotype.
- Published
- 2022
- Full Text
- View/download PDF
18. Use of 18F-fluorodeoxyglucose positron emission tomography to standardize clinical trial recruitment in Takayasu's arteritis.
- Author
-
Quinn, Kaitlin A, Alessi, Hugh D, Ponte, Cristina, Rose, Emily, Ahlman, Mark A, Redmond, Christopher, Luo, Yiming, Bolek, Ertugrul Cagri, Langford, Carol A, Merkel, Peter A, and Grayson, Peter C
- Subjects
HUMAN research subjects ,CLINICAL trials ,CONFIDENCE intervals ,PATIENT selection ,TAKAYASU arteritis ,RADIOPHARMACEUTICALS ,POSITRON emission tomography ,ELIGIBILITY (Social aspects) ,CASE studies ,DESCRIPTIVE statistics ,DEOXY sugars ,PHYSICIANS - Abstract
Objectives To assess whether data from
18 F-fluorodeoxyglucose (FDG) PET should be incorporated into eligibility criteria for clinical trials in Takayasu's arteritis (TAK). Methods The study was conducted in two parts. Part one was an international online survey among physicians with experience managing TAK to determine, using clinical vignettes, whether FDG-PET data influence decisions about enrolment in trials. Part two used patient data from an observational cohort study in TAK to assess agreement regarding decisions about enrolment into trials, based on clinical assessment with and without incorporation of FDG-PET data. Results In part one, 68 physicians responded to the survey. Most physicians had used FDG-PET to diagnose TAK (82%) or monitor disease activity (66%). In vignettes representing active clinical disease, FDG-PET findings increased physician confidence in disease assessment and reduced outlier assessments. The greatest variability in decisions regarding enrolment into trials was observed in vignettes representing constitutional symptoms alone and elevated acute-phase reactants. In these cases, FDG-PET findings influenced decisions about enrolment and improved physician confidence. In multivariable models, FDG-PET findings were 1.29 times more strongly associated with enrolment decisions compared with levels of acute-phase reactants. In part two, incorporation of FDG-PET data significantly improved agreement about enrolment decisions between raters [inter-rater reliability (IRR) = 0.68 (95% CI 0.67, 0.69) to IRR = 0.88 (95% CI 0.87, 0.89); P < 0.01]. Conclusions Incorporation of FDG-PET data into assessment of TAK influences decisions about enrolment of patients into trials, improves physician confidence about clinical assessment and could help reduce variability in study populations. Future trials in TAK should consider incorporating FDG-PET data into eligibility criteria. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
19. Physician Global Assessment as a Disease Activity Measure for Relapsing Polychondritis.
- Author
-
Rose, Emily, Ferrada, Marcela A., Quinn, Kaitlin A., Goodspeed, Wendy, Arnaud, Laurent, Sharma, Aman, Yoshifuji, Hajime, Kim, Jeff, Allen, Clint, Sirajuddin, Arlene, Chen, Marcus, and Grayson, Peter C.
- Abstract
Objective: Relapsing polychondritis (RP) is a systemic inflammatory disorder of cartilage that lacks validated disease activity measures. Our objective was to test physician global assessment (PhGA), a measure of disease activity commonly used in rheumatic diseases, in a cohort of patients with RP, which has not been done before.Methods: Adult patients in an observational cohort of RP underwent standardized, comprehensive evaluation at approximately 6-month intervals. PhGA was scored by 3 physicians from the evaluating institution on a scale of 0-10 for each visit. A random subset of 20 visits was scored by 3 independent physicians not affiliated with the evaluating institution. Treatment change between consecutive visits was categorized as increased, decreased, or unchanged.Results: In total, 78 patients were evaluated over 164 visits. The intraclass correlation coefficient (ICC2,1 ) for the 3 raters from the evaluating institution was excellent (0.79 [95% confidence interval (95% CI) 0.73, 0.84]) but was poor in the subset of cases scored by the additional raters (ICC2,1 0.27 [95% CI -0.01, 0.53]). Median PhGA was 3 (range 0-7). PhGA weakly correlated with C-reactive protein level (rs = 0.30, P < 0.01). In response to increased treatment, median PhGA decreased from 3 (interquartile range [IQR] 2, 4) to 2 (IQR 2, 3) (P < 0.01) but rarely went to 0.Conclusion: Within a single center, PhGA can be used to quantify disease activity and monitor disease response in RP. Persistent disease activity despite treatment, rather than a relapsing-remitting pattern, is observed for most patients with RP. Reliability of PhGA may not generalize across different institutions. A validated disease-specific activity index is needed in RP. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
20. Somatic mutations in rheumatological diseases: VEXAS syndrome and beyond.
- Author
-
Sikora, Keith A, Wells, Kristina V, Bolek, Ertugrul Cagri, Jones, Adrianna I, and Grayson, Peter C
- Subjects
GENETIC mutation ,PROFESSIONS ,INFLAMMATION ,CLINICAL competence ,RHEUMATISM ,HEMATOPOIESIS ,AUTOINFLAMMATORY diseases - Abstract
Discovery of the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome demonstrates that somatic mutations in haematological precursor cells can cause adult-onset, complex inflammatory disease. Unlike germline mutations, somatic mutations occur throughout the lifespan, are restricted to specific tissue types, and may play a causal role in non-heritable rheumatological diseases, especially conditions that start in later life. Improvements in sequencing technology have enabled researchers and clinicians to detect somatic mutations in various tissue types, especially blood. Understanding the relationships between cell-specific acquired mutations and inflammation is likely to yield key insights into causal factors that underlie many rheumatological diseases. The objective of this review is to detail how somatic mutations are likely to be relevant to clinicians who care for patients with rheumatological diseases, with particular focus on the pathogenetic mechanisms of the VEXAS syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis.
- Author
-
Michailidou, Despina, Duvvuri, Bhargavi, Kuley, Runa, Cuthbertson, David, Grayson, Peter C., Khalidi, Nader A., Koening, Curry L., Langford, Carol A., McAlear, Carol A., Moreland, Larry W., Pagnoux, Christian, Seo, Philip, Specks, Ulrich, Sreih, Antoine G., Warrington, Kenneth J., Mustelin, Tomas, Monach, Paul A., Merkel, Peter A., and Lood, Christian
- Published
- 2022
- Full Text
- View/download PDF
22. Clinicopathologic Associations in a Large International Cohort of Patients With Giant Cell Arteritis.
- Author
-
Putman, Michael S., Gribbons, K. Bates, Ponte, Cristina, Robson, Joanna, Suppiah, Ravi, Craven, Anthea, Watts, Richard, Luqmani, Raashid, Merkel, Peter A., Archer, Amy M., and Grayson, Peter C.
- Subjects
GIANT cell arteritis ,MONONUCLEAR leukocytes ,CLINICAL pathology ,TEMPORAL arteries ,REGRESSION analysis ,VISION disorders - Abstract
Objective: In addition to aiding in diagnosis, histopathologic findings from temporal artery biopsy (TAB) specimens in giant cell arteritis (GCA) may be valuable for their associations with clinical features of the disease. This study was undertaken to compare histopathologic findings on TAB with biopsy interpretation and demographic, clinical, and imaging features at time of diagnosis. Methods: Patients with a clinical diagnosis of GCA who had a TAB were selected from an international, multicenter observational cohort of vasculitis. Associations between demographic, clinical, radiographic, and histopathologic features were identified using bivariate testing and multivariate regression modeling. Results: Of 705 patients with GCA who underwent TAB, 69% had histopathologic evidence of definite vasculitis. Specific histopathologic findings included the presence of giant cells (51%), fragmentation of the internal elastic lamina (41%), intimal thickening (33%), and predominantly mononuclear leukocyte infiltration (32%). Histopathologic interpretation of definite vasculitis was independently associated with giant cells (odds ratio [OR] 151.8 [95% confidence interval (95% CI) 60.2–551.6]), predominantly mononuclear leukocyte infiltration (OR 11.8 [95% CI 5.9–24.9]), and fragmentation of the internal elastic lamina (OR 3.7 [95% CI 1.9–7.4]). A halo sign on temporal artery ultrasound and luminal damage of large arteries on angiography were significantly associated with presence of giant cells (OR 2.6 [95% CI 1.1–6.5] and OR 2.4 [95% CI 1.1–5.2], respectively). Specific histopathologic findings were associated with older age, but no associations were identified with vision loss or other clinical features. Conclusion: Histopathologic findings in GCA are strongly associated with the clinical diagnosis of GCA but have a limited role in identifying patterns of disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Diseases of blood vessels: Immune system involvement in vasculitis and vasculopathy.
- Author
-
Grayson, Peter C. and Kaplan, Mariana J.
- Subjects
VASCULAR diseases ,VASCULITIS ,PHOSPHOLIPID antibodies ,IMMUNE system ,TRANSFORMING growth factors-beta ,MARFAN syndrome - Abstract
This article is a contribution to the special issue on: Inflammation in vascular diseases - Guest Editors: Mariana Kaplan & Peter Grayson In 1865, a 27-year-old man was hospitalized at the University of Freiburg, Germany, for a rapidly progressive, systemic illness. 8285055 11 Harper RL, Ferrante EA, Boehm M. Development of vascular disease models to explore disease causation and pathomechanisms of rare vascular diseases. I Harper i et al. detail various methods to create patient-specific vascular disease models including use of primary cells derived from various patient biospecimens coupled with in vitro and in vivo vascular models and provide examples of successful approaches to study various rare vascular diseases [[11]]. Using Takayasu's arteritis, a disease predominantly of the young, and giant cell arteritis, a disease exclusive to later adulthood, the authors compare age of the host as a critical intrinsic factor that influences the immunologic landscape of different inflammatory forms of vascular disease. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
24. Discordance in patient and physician global assessment in relapsing polychondritis.
- Author
-
Rose, Emily, Ferrada, Marcela A, Quinn, Kaitlin A, Arnaud, Laurent, Goodspeed, Wendy, Kim, Jeff, Allen, Clint, Sirajuddin, Arlene, Chen, Marcus, and Grayson, Peter C
- Subjects
SELF-evaluation ,CARTILAGE diseases ,PHYSICIANS' attitudes ,HEALTH outcome assessment ,HEALTH surveys ,SEVERITY of illness index ,PATIENTS' attitudes ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,PSYCHOLOGY of the sick ,MEDICAL needs assessment ,EVALUATION - Abstract
Objectives Relapsing polychondritis (RP) is a rare, heterogeneous, systemic inflammatory disease that targets cartilage. Patient-reported outcome measures may differ from physician assessment. This study compared patient global assessment (PtGA) and physician global assessment (PhGA) scores in a prospective cohort of patients with RP. Methods Adult patients with RP underwent a standardized comprehensive evaluation at ∼6 month intervals. At each visit, three physicians scored PhGA by consensus. The patient independently completed four patient-reported outcomes: PtGA, 36-item Short Form Health Survey (SF-36), Brief Illness Perception Questionnaire (BIPQ) and Multidimensional Fatigue Inventory (MFI). Patient–physician discordance was defined as a difference between PtGA and PhGA of ≥3 on a 0–10 scale. Results A total of 76 patients were evaluated over 154 visits. The median PhGA was 3 [interquartile range (IQR) 2–3] and the median PtGA was 5 (IQR 4–7). PtGA and PhGA were concordant in 66 visits (42.9%) and patients scored disease severity ≥3 points higher than physicians scored disease activity (positive discordance) in 84 visits (54.5%). Compared with visits with concordance, visits with positive discordance were associated with significantly worse scores on the MFI, BIPQ, SF-36 physical component score and SF-36 mental component score. Conclusion Patients with RP typically self-report high PtGA that does not align with PhGA. Discordance is likely driven by the high physical and psychological burden of illness experienced by patients. Multifaceted treatment approaches that address the burden of disease in RP from the patient perspective are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. VEXAS Syndrome: A Case Series From a Single‐Center Cohort of Italian Patients With Vasculitis.
- Author
-
Muratore, Francesco, Marvisi, Chiara, Castrignanò, Paola, Nicoli, Davide, Farnetti, Enrico, Bonanno, Orsola, Longo, Rosina, Zaldini, Piera, Galli, Elena, Balanda, Nicholas, Beck, David B., Grayson, Peter C., Pipitone, Nicolò, Boiardi, Luigi, and Salvarani, Carlo
- Subjects
ENZYME metabolism ,ACQUISITION of data methodology ,INFLAMMATION ,RETROSPECTIVE studies ,KARYOTYPES ,ANTINEUTROPHIL cytoplasmic antibodies ,RISK assessment ,MEDICAL records ,INFLAMMATORY mediators ,CYTOGENETICS ,AUTOINFLAMMATORY diseases ,VASCULITIS ,PHENOTYPES ,DISEASE risk factors ,DISEASE complications - Abstract
Objective: To identify patients with VEXAS syndrome (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome) from a single‐center cohort of Italian patients with vasculitis, using a clinically oriented phenotype‐first approach. Methods: We retrospectively reviewed the clinical records of 147 consecutive male patients followed up in our vasculitis clinic from 2013 to date. All patients with a diagnosis of vasculitis and treatment‐resistant manifestations of inflammation, persistently elevated inflammation markers, and hematologic abnormalities were identified. Bone marrow aspirates were examined for the presence of vacuoles. Sequencing of ubiquitin‐activating enzyme E1 (UBA‐1) was performed using genomic DNA from peripheral blood leukocytes or bone marrow tissue. Results: Seven patients with vasculitis and concomitant features of VEXAS syndrome were identified. A final diagnosis of VEXAS syndrome was made in 3 of the 5 patients who underwent sequencing of UBA‐1 (diagnosis was made postmortem for 1 patient). In all 3 patients, examination of the bone marrow aspirate revealed vacuoles characteristic of VEXAS syndrome, and all 3 patients met the definitive World Health Organization criteria for myelodysplastic syndrome. Cytogenetic analysis showed normal karyotypes in all 3 patients. Conclusion: To our knowledge, this is the first report of VEXAS syndrome associated with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. Our data emphasize the need to consider VEXAS syndrome when evaluating patients with various forms of systemic vasculitis. The novel association between VEXAS syndrome and ANCA‐associated vasculitis reported herein warrants further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis.
- Author
-
Suppiah, Ravi, Robson, Joanna C., Grayson, Peter C., Ponte, Cristina, Craven, Anthea, Khalid, Sara, Judge, Andrew, Hutchings, Andrew, Merkel, Peter A., Luqmani, Raashid A., Watts, Richard A., and DCVAS INVESTIGATORS
- Subjects
AUTOANTIBODIES ,RESEARCH ,BIOPSY ,RESEARCH evaluation ,RHEUMATOLOGY ,RESEARCH methodology ,PROTEOLYTIC enzymes ,DIFFERENTIAL diagnosis ,EVALUATION research ,COMPARATIVE studies ,SENSITIVITY & specificity (Statistics) ,PROFESSIONAL associations ,OXIDOREDUCTASES ,VASCULITIS ,LONGITUDINAL method - Abstract
Objective: To develop and validate classification criteria for microscopic polyangiitis (MPA).Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: (1) identification of candidate items using consensus methodology, (2) prospective collection of candidate items present at the time of diagnosis, (3) data-driven reduction of the number of candidate items, (4) expert panel review of cases to define the reference diagnosis and (5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators.Results: The development set for MPA consisted of 149 cases of MPA and 408 comparators. The validation set consisted of an additional 142 cases of MPA and 414 comparators. From 91 candidate items, regression analysis identified 10 items for MPA, 6 of which were retained. The final criteria and their weights were as follows: perinuclear antineutrophil cytoplasmic antibody (ANCA) or anti-myeloperoxidase-ANCA positivity (+6), pauci-immune glomerulonephritis (+3), lung fibrosis or interstitial lung disease (+3), sino-nasal symptoms or signs (-3), cytoplasmic ANCA or anti-proteinase 3 ANCA positivity (-1) and eosinophil count ≥1×109/L (-4). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having MPA with a cumulative score of ≥5 points. When these criteria were tested in the validation data set, the sensitivity was 91% (95% CI 85% to 95%) and the specificity was 94% (95% CI 92% to 96%).Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for MPA are now validated for use in clinical research. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
27. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis.
- Author
-
Robson, Joanna C., Grayson, Peter C., Ponte, Cristina, Suppiah, Ravi, Craven, Anthea, Judge, Andrew, Khalid, Sara, Hutchings, Andrew, Watts, Richard A., Merkel, Peter A., Luqmani, Raashid A., and DCVAS Investigators
- Abstract
Objective: To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA).Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: (1) identification of candidate criteria items using consensus methodology, (2) prospective collection of candidate items present at the time of diagnosis, (3) data-driven reduction of the number of candidate items, (4) expert panel review of cases to define the reference diagnosis and (5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators.Results: The development set for GPA consisted of 578 cases of GPA and 652 comparators. The validation set consisted of an additional 146 cases of GPA and 161 comparators. From 91 candidate items, regression analysis identified 26 items for GPA, 10 of which were retained. The final criteria and their weights were as follows: bloody nasal discharge, nasal crusting or sino-nasal congestion (+3); cartilaginous involvement (+2); conductive or sensorineural hearing loss (+1); cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti-proteinase 3 ANCA positivity (+5); pulmonary nodules, mass or cavitation on chest imaging (+2); granuloma or giant cells on biopsy (+2); inflammation or consolidation of the nasal/paranasal sinuses on imaging (+1); pauci-immune glomerulonephritis (+1); perinuclear ANCA or antimyeloperoxidase ANCA positivity (-1); and eosinophil count ≥1×109 /L (-4). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having GPA if the cumulative score was ≥5 points. When these criteria were tested in the validation data set, the sensitivity was 93% (95% CI 87% to 96%) and the specificity was 94% (95% CI 89% to 97%).Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for GPA demonstrate strong performance characteristics and are validated for use in research. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
28. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis.
- Author
-
Grayson, Peter C., Ponte, Cristina, Suppiah, Ravi, Robson, Joanna C., Craven, Anthea, Judge, Andrew, Khalid, Sara, Hutchings, Andrew, Luqmani, Raashid A., Watts, Richard A., Merkel, Peter A., and DCVAS Study Group
- Abstract
Objective: To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA).Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: (1) identification of candidate criteria items using consensus methodology, (2) prospective collection of candidate items present at the time of diagnosis, (3) data-driven reduction of the number of candidate items, (4) expert panel review of cases to define the reference diagnosis and (5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators.Results: The development set for EGPA consisted of 107 cases of EGPA and 450 comparators. The validation set consisted of an additional 119 cases of EGPA and 437 comparators. From 91 candidate items, regression analysis identified 11 items for EPGA, 7 of which were retained. The final criteria and their weights were as follows: maximum eosinophil count ≥1×109/L (+5), obstructive airway disease (+3), nasal polyps (+3), cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti-proteinase 3-ANCA positivity (-3), extravascular eosinophilic predominant inflammation (+2), mononeuritis multiplex/motor neuropathy not due to radiculopathy (+1) and haematuria (-1). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having EGPA if the cumulative score was ≥6 points. When these criteria were tested in the validation data set, the sensitivity was 85% (95% CI 77% to 91%) and the specificity was 99% (95% CI 98% to 100%).Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis demonstrate strong performance characteristics and are validated for use in research. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
29. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis.
- Author
-
Robson, Joanna C., Grayson, Peter C., Ponte, Cristina, Suppiah, Ravi, Craven, Anthea, Judge, Andrew, Khalid, Sara, Hutchings, Andrew, Watts, Richard A., Merkel, Peter A., Luqmani, Raashid A., Gatenby, Paul, Hill, Catherine, Ranganathan, Dwarakanathan, Kronbichler, Andreas, Blockmans, Daniel, Barra, Lillian, Carette, Simon, Pagnoux, Christian, and Dhindsa, Navjot
- Subjects
CONSENSUS (Social sciences) ,EOSINOPHILS ,CONFIDENCE intervals ,RHEUMATOLOGY ,RESEARCH methodology ,PARANASAL sinus diseases ,ANTINEUTROPHIL cytoplasmic antibodies ,GRANULOMATOSIS with polyangiitis ,LOGISTIC regression analysis ,SENSITIVITY & specificity (Statistics) - Abstract
Objective: To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate criteria items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data‐driven reduction of the number of candidate items, 4) expert panel review of cases to define the reference diagnosis, and 5) derivation of a points‐based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators. Results: The development set for GPA consisted of 578 cases of GPA and 652 comparators. The validation set consisted of an additional 146 cases of GPA and 161 comparators. From 91 candidate items, regression analysis identified 26 items for GPA, 10 of which were retained. The final criteria and their weights were as follows: bloody nasal discharge, nasal crusting, or sino‐nasal congestion (+3); cartilaginous involvement (+2); conductive or sensorineural hearing loss (+1); cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti–proteinase 3 ANCA positivity (+5); pulmonary nodules, mass, or cavitation on chest imaging (+2); granuloma or giant cells on biopsy (+2); inflammation or consolidation of the nasal/paranasal sinuses on imaging (+1); pauci‐immune glomerulonephritis (+1); perinuclear ANCA or antimyeloperoxidase ANCA positivity (−1); and eosinophil count ≥1 × 109/liter (−4). After excluding mimics of vasculitis, a patient with a diagnosis of small‐ or medium‐vessel vasculitis could be classified as having GPA if the cumulative score was ≥5 points. When these criteria were tested in the validation data set, the sensitivity was 93% (95% confidence interval [95% CI] 87–96%) and the specificity was 94% (95% CI 89–97%). Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for GPA demonstrate strong performance characteristics and are validated for use in research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
30. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis.
- Author
-
Suppiah, Ravi, Robson, Joanna C., Grayson, Peter C., Ponte, Cristina, Craven, Anthea, Khalid, Sara, Judge, Andrew, Hutchings, Andrew, Merkel, Peter A., Luqmani, Raashid A., Watts, Richard A., Gatenby, Paul, Hill, Catherine, Ranganathan, Dwarakanathan, Kronbichler, Andreas, Blockmans, Daniel, Barra, Lillian, Carette, Simon, Pagnoux, Christian, and Dhindsa, Navjot
- Subjects
COMMITTEES ,CONFIDENCE intervals ,RHEUMATOLOGY ,ANTINEUTROPHIL cytoplasmic antibodies ,INTERSTITIAL lung diseases ,DESCRIPTIVE statistics ,LOGISTIC regression analysis ,GLOMERULONEPHRITIS ,ERYTHROCYTES ,MICROSCOPIC polyangiitis ,LONGITUDINAL method ,VASCULITIS - Abstract
Objective: To develop and validate classification criteria for microscopic polyangiitis (MPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data‐driven reduction of the number of candidate items, 4) expert panel review of cases to define the reference diagnosis, and 5) derivation of a points‐based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators. Results: The development set for MPA consisted of 149 cases of MPA and 408 comparators. The validation set consisted of an additional 142 cases of MPA and 414 comparators. From 91 candidate items, regression analysis identified 10 items for MPA, 6 of which were retained. The final criteria and their weights were as follows: perinuclear antineutrophil cytoplasmic antibody (ANCA) or anti–myeloperoxidase‐ANCA positivity (+6), pauci‐immune glomerulonephritis (+3), lung fibrosis or interstitial lung disease (+3), sino‐nasal symptoms or signs (−3), cytoplasmic ANCA or anti–proteinase 3 ANCA positivity (−1), and eosinophil count ≥1 × 109/liter (−4). After excluding mimics of vasculitis, a patient with a diagnosis of small‐ or medium‐vessel vasculitis could be classified as having MPA with a cumulative score of ≥5 points. When these criteria were tested in the validation data set, the sensitivity was 91% (95% confidence interval [95% CI] 85–95%) and the specificity was 94% (95% CI 92–96%). Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for MPA are now validated for use in clinical research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis.
- Author
-
Grayson, Peter C., Ponte, Cristina, Suppiah, Ravi, Robson, Joanna C., Craven, Anthea, Judge, Andrew, Khalid, Sara, Hutchings, Andrew, Luqmani, Raashid A., Watts, Richard A., Merkel, Peter A., Gatenby, Paul, Hill, Catherine, Ranganathan, Dwarakanathan, Kronbichler, Andreas, Blockmans, Daniel, Barra, Lillian, Carette, Simon, Pagnoux, Christian, and Dhindsa, Navjot
- Subjects
CONSENSUS (Social sciences) ,EOSINOPHILS ,CONFIDENCE intervals ,RHEUMATOLOGY ,RESEARCH methodology ,PARANASAL sinus diseases ,ANTINEUTROPHIL cytoplasmic antibodies ,CHURG-Strauss syndrome ,DESCRIPTIVE statistics ,LOGISTIC regression analysis ,SENSITIVITY & specificity (Statistics) - Abstract
Objective: To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate criteria items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data‐driven reduction of the number of candidate items, 4) expert panel review of cases to define the reference diagnosis, and 5) derivation of a points‐based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators. Results: The development set for EGPA consisted of 107 cases of EGPA and 450 comparators. The validation set consisted of an additional 119 cases of EGPA and 437 comparators. From 91 candidate items, regression analysis identified 11 items for EPGA, 7 of which were retained. The final criteria and their weights were as follows: maximum eosinophil count ≥1 × 109/liter (+5), obstructive airway disease (+3), nasal polyps (+3), cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti–proteinase 3 ANCA positivity (−3), extravascular eosinophilic predominant inflammation (+2), mononeuritis multiplex/motor neuropathy not due to radiculopathy (+1), and hematuria (−1). After excluding mimics of vasculitis, a patient with a diagnosis of small‐ or medium‐vessel vasculitis could be classified as having EGPA if the cumulative score was ≥6 points. When these criteria were tested in the validation data set, the sensitivity was 85% (95% confidence interval [95% CI] 77–91%) and the specificity was 99% (95% CI 98–100%). Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for EGPA demonstrate strong performance characteristics and are validated for use in research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Pulmonary involvement in primary systemic vasculitides.
- Author
-
Makhzoum, Jean-Paul, Grayson, Peter C, Ponte, Cristina, Robson, Joanna, Suppiah, Ravi, Watts, Richard A, Luqmani, Raashid, Merkel, Peter A, Pagnoux, Christian, and Collaborators, for the DCVAS
- Subjects
HEMOPTYSIS ,LUNG diseases ,FIBROSIS ,DYSPNEA ,TAKAYASU arteritis ,GRANULOMATOSIS with polyangiitis ,POLYARTERITIS nodosa ,VASCULITIS ,MICROSCOPIC polyangiitis ,DISEASE risk factors ,DISEASE complications - Abstract
Objectives This study describes the spectrum and initial impact of pulmonary manifestations in the primary systemic vasculitides. Methods Description and comparison of pulmonary manifestations in adults with Takayasu's arteritis (TAK), GCA, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic GPA (EGPA), polyarteritis nodosa (PAN) and IgA vasculitis (IgAV), using data collected within the Diagnostic and Classification Criteria in Vasculitis study. Results Data from 1952 patients with primary vasculitides were included: 170 TAK, 657 GCA, 555 GPA, 223 MPA, 146 EGPA, 153 IgAV and 48 PAN. Pulmonary manifestations were observed in patients with TAK (21.8%), GCA (15.8%), GPA (64.5%), MPA (65.9%), EGPA (89.0%), PAN (27.1%) and IgAV (5.9%). Dyspnoea occurred in patients with TAK (14.7%), GCA (7.8%), GPA (41.8%), MPA (43.5%), EGPA (65.8%), PAN (18.8%) and IgAV (2.6%). Cough was reported in TAK (7.6%), GCA (9.3%), GPA (34.8%), MPA (37.7%), EGPA (55.5%), PAN (16.7%) and IgAV (3.3%). Haemoptysis occurred mainly in patients with ANCA-associated vasculitis (AAV). Fibrosis on imaging at diagnosis was documented in GPA (1.9%), MPA (24.9%) and EGPA (6.3%). Only patients with AAV (GPA 2.7%, MPA 2.7% and EGPA 3.4%) required mechanical ventilation. At 6 months, the presence of at least one pulmonary item in the Vasculitis Damage Index was observed in TAK (4.1%), GCA (3.3%), GPA (15.4%), MPA (28.7%), EGPA (52.7%), PAN (6.2%) and IgAV (1.3%). Conclusion Pulmonary manifestations can occur in all primary systemic vasculitides, but are more frequent and more often associated with permanent damage in AAV. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Reply LTE, On Semi-quantitative Methods for Assessing Vascular 18FDG-PET Activity in Large- Vessel Vasculitis.
- Author
-
Ahlman, Mark A., Maass-Moreno, Roberto, and Grayson, Peter C.
- Published
- 2021
- Full Text
- View/download PDF
34. Comparing Semi-quantitative and Qualitative Methods of Vascular FDG-PET Activity Measurement in Large-Vessel Vasculitis.
- Author
-
Dashora, Himanshu R., Rosenblum, Joel S., Quinn, Kaitlin A., Alessi, Hugh, Novakovich, Elaine, Saboury, Babak, Ahlman, Mark A., and Grayson, Peter C.
- Published
- 2021
- Full Text
- View/download PDF
35. Reply LTE, On Semi-quantitative Methods for Assessing Vascular 18FDG-PET Activity in Large- Vessel Vasculitis.
- Author
-
Ahlman, Mark A., Maass-Moreno, Roberto, and Grayson, Peter C
- Published
- 2021
- Full Text
- View/download PDF
36. Comparing Semi-quantitative and Qualitative Methods of Vascular FDG-PET Activity Measurement in Large-Vessel Vasculitis.
- Author
-
Dashora, Himanshu R., Rosenblum, Joel S., Quinn, Kaitlin A., Alessi, Hugh, Novakovich, Elaine, Saboury, Babak, Ahlman, Mark A., and Grayson, Peter C.
- Published
- 2021
- Full Text
- View/download PDF
37. Comparing Semi-quantitative and Qualitative Methods of Vascular FDG-PET Activity Measurement in Large-Vessel Vasculitis.
- Author
-
Dashora, Himanshu R., Rosenblum, Joel S., Quinn, Kaitlin A., Alessi, Hugh, Novakovich, Elaine, Saboury, Babak, Ahlman, Mark A., and Grayson, Peter C.
- Published
- 2021
- Full Text
- View/download PDF
38. Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis.
- Author
-
Quinn, Kaitlin A., Dashora, Himanshu, Novakovich, Elaine, Ahlman, Mark A., and Grayson, Peter C.
- Subjects
STATISTICS ,SCIENTIFIC observation ,TOCILIZUMAB ,INFLAMMATION ,GIANT cell arteritis ,REGRESSION analysis ,RADIOPHARMACEUTICALS ,DESCRIPTIVE statistics ,DEOXY sugars ,DATA analysis ,LONGITUDINAL method ,PHARMACODYNAMICS - Abstract
Objectives To evaluate the time-dependent effects of tocilizumab on vascular inflammation as measured by
18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) in GCA. Methods Patients with GCA treated with tocilizumab were selected from a prospective, observational cohort. Patients underwent FDG-PET at the baseline visit prior to initiation of tocilizumab and at subsequent follow-up visits performed at 6-month intervals. All imaging findings were interpreted blinded to clinical data. The PET vascular activity score (PETVAS) was used to quantify arterial FDG uptake. Wilcoxon signed rank test was used to compare change in PETVAS between visits. Linear regression was used to determine change in PETVAS over multiple timepoints. Results Twenty-five patients with GCA were included. All patients had physician-determined active vasculitis at the baseline visit by clinical assessment and FDG-PET interpretation. PETVAS was significantly reduced in association with tocilizumab treatment from the baseline to the most recent follow-up visit [24.0 (IQR 22.3–27.0) vs 18.5 (IQR 15.3–23.8); P <0.01]. A significant reduction in PETVAS was observed over a two-year treatment period (P <0.01 for linear trend), with a similar degree of improvement in both the first and second years of treatment. Repeat FDG-PET scans after tocilizumab discontinuation showed worsening PET activity in five out of six patients, with two patients subsequently experiencing clinical relapse. Conclusion Treatment of patients with GCA with tocilizumab was associated with both clinical improvement and reduction of vascular inflammation as measured by serial FDG-PET. Future clinical trials in GCA should study direct treatment effect on vascular inflammation as an outcome measure. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
39. Dynamic Changes in the Nasal Microbiome Associated With Disease Activity in Patients With Granulomatosis With Polyangiitis.
- Author
-
Rhee, Rennie L., Lu, Jiarui, Bittinger, Kyle, Lee, Jung‐Jin, Mattei, Lisa M., Sreih, Antoine G., Chou, Sherry, Miner, Jonathan J., Cohen, Noam A., Kelly, Brendan J., Lee, Hongzhe, Grayson, Peter C., Collman, Ronald G., and Merkel, Peter A.
- Subjects
RNA analysis ,SEQUENCE analysis ,CORYNEBACTERIUM ,AUTOIMMUNE diseases ,ANTINEUTROPHIL cytoplasmic antibodies ,NOSE ,DISEASE relapse ,HUMAN microbiota ,STAPHYLOCOCCUS ,STATISTICAL models ,LONGITUDINAL method - Abstract
Objective: Little is known about temporal changes in nasal bacteria in granulomatosis with polyangiitis (GPA). This study was undertaken to examine longitudinal changes in the nasal microbiome in association with relapse in GPA patients. Methods: Bacterial 16S ribosomal RNA gene sequencing was performed on nasal swabs from 19 patients with GPA who were followed up longitudinally for a total of 78 visits, including 9 patients who experienced a relapse and 10 patients who remained in remission. Relative abundance of bacteria and ratios between bacteria were examined. Generalized estimating equation models were used to evaluate the association between bacterial composition and 1) disease activity and 2) levels of antineutrophil cytoplasmic antibody (ANCA) with specificity for proteinase 3 (PR3), adjusted for medication. Results: Corynebacterium and Staphylococcus were the most abundant bacterial genera across all nasal samples. Patients with quiescent disease maintained a stable ratio of Corynebacterium to Staphylococcus across visits. In contrast, in patients who experienced a relapse, a significantly lower ratio was observed at the visit prior to relapse, followed by a higher ratio at the time of relapse (adjusted P < 0.01). Species‐level analysis identified an association between a higher abundance of nasal Corynebacterium tuberculostearicum and 1) relapse (adjusted P = 0.04) and 2) higher PR3‐ANCA levels (adjusted P = 0.02). Conclusion: In GPA, significant changes occur in the nasal microbiome over time and are associated with disease activity. The occurrence of these changes months prior to the onset of relapse supports a pathogenic role of nasal bacteria in GPA. Our results uphold existing hypotheses implicating Staphylococcus as an instigator of disease and have generated a novel finding involving Corynebacterium as a potential mediator of disease in GPA. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
- Author
-
Chung, Sharon A., Langford, Carol A., Maz, Mehrdad, Abril, Andy, Gorelik, Mark, Guyatt, Gordon, Archer, Amy M., Conn, Doyt L., Full, Kathy A., Grayson, Peter C., Ibarra, Maria F., Imundo, Lisa F., Kim, Susan, Merkel, Peter A., Rhee, Rennie L., Seo, Philip, Stone, John H., Sule, Sangeeta, Sundel, Robert P., and Vitobaldi, Omar I.
- Subjects
VASCULITIS ,VASCULAR diseases ,ANTINEUTROPHIL cytoplasmic antibodies ,AUTOANTIBODIES ,CHURG-Strauss syndrome ,AUTOIMMUNE disease diagnosis ,CONSENSUS (Social sciences) ,RHEUMATOLOGY ,AUTOIMMUNE diseases ,EVIDENCE-based medicine ,SEVERITY of illness index ,TREATMENT effectiveness ,DECISION making ,IMMUNOSUPPRESSIVE agents - Abstract
Objective: To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).Methods: Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel.Results: We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low-quality evidence supporting the recommendations.Conclusion: This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
41. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa.
- Author
-
Chung, Sharon A., Gorelik, Mark, Langford, Carol A., Maz, Mehrdad, Abril, Andy, Guyatt, Gordon, Archer, Amy M., Conn, Doyt L., Full, Kathy A., Grayson, Peter C., Ibarra, Maria F., Imundo, Lisa F., Kim, Susan, Merkel, Peter A., Rhee, Rennie L., Seo, Philip, Stone, John H., Sule, Sangeeta, Sundel, Robert P., and Vitobaldi, Omar I.
- Subjects
POLYARTERITIS nodosa ,ARTERITIS ,COLLAGEN diseases ,RHEUMATOLOGY ,JOINT diseases ,THERAPEUTIC use of glucocorticoids ,GLUCOCORTICOIDS ,CONSENSUS (Social sciences) ,RESEARCH ,COMBINATION drug therapy ,RESEARCH methodology ,EVIDENCE-based medicine ,MEDICAL cooperation ,EVALUATION research ,SEVERITY of illness index ,TREATMENT effectiveness ,COMPARATIVE studies ,CYCLOPHOSPHAMIDE ,DECISION making ,IMMUNOSUPPRESSIVE agents - Abstract
Objective: To provide evidence-based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN).Methods: Twenty-one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for systemic, non-hepatitis B-related PAN. Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel.Results: We present 16 recommendations and 1 ungraded position statement for PAN. Most recommendations were graded as conditional due to the paucity of evidence. These recommendations support early treatment of severe PAN with cyclophosphamide and glucocorticoids, limiting toxicity through minimizing long-term exposure to both treatments, and the use of imaging and tissue biopsy for disease diagnosis. These recommendations endorse minimizing risk to the patient by using established therapy at disease onset and identify new areas where adjunctive therapy may be warranted.Conclusion: These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with PAN. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
42. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.
- Author
-
Maz, Mehrdad, Chung, Sharon A., Abril, Andy, Langford, Carol A., Gorelik, Mark, Guyatt, Gordon, Archer, Amy M., Conn, Doyt L., Full, Kathy A., Grayson, Peter C., Ibarra, Maria F., Imundo, Lisa F., Kim, Susan, Merkel, Peter A., Rhee, Rennie L., Seo, Philip, Stone, John H., Sule, Sangeeta, Sundel, Robert P., and Vitobaldi, Omar I.
- Subjects
GIANT cell arteritis ,TAKAYASU arteritis ,ARTERITIS ,SKIN diseases ,PEDIATRICS ,THERAPEUTIC use of glucocorticoids ,GIANT cell arteritis diagnosis ,CONSENSUS (Social sciences) ,GLUCOCORTICOIDS ,RESEARCH ,COMBINATION drug therapy ,RHEUMATOLOGY ,RESEARCH methodology ,EVIDENCE-based medicine ,MEDICAL cooperation ,EVALUATION research ,TREATMENT effectiveness ,COMPARATIVE studies ,DECISION making ,IMMUNOSUPPRESSIVE agents - Abstract
Objective: To provide evidence-based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis.Methods: Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel.Results: We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid-sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions.Conclusion: These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
43. Comparing Semi-quantitative and Qualitative Methods of Vascular FDG-PET Activity Measurement in Large-Vessel Vasculitis.
- Author
-
Dashora, Himanshu R., Rosenblum, Joel S., Quinn, Kaitlin A., Alessi, Hugh, Novakovich, Elaine, Saboury, Babak, Ahlman, Mark A., and Grayson, Peter C.
- Published
- 2021
- Full Text
- View/download PDF
44. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis.
- Author
-
Chung, Sharon A., Langford, Carol A., Maz, Mehrdad, Abril, Andy, Gorelik, Mark, Guyatt, Gordon, Archer, Amy M., Conn, Doyt L., Full, Kathy A., Grayson, Peter C., Ibarra, Maria F., Imundo, Lisa F., Kim, Susan, Merkel, Peter A., Rhee, Rennie L., Seo, Philip, Stone, John H., Sule, Sangeeta, Sundel, Robert P., and Vitobaldi, Omar I.
- Subjects
GRANULOMATOSIS with polyangiitis diagnosis ,THERAPEUTIC use of monoclonal antibodies ,RITUXIMAB ,RHEUMATOLOGY ,ANTINEUTROPHIL cytoplasmic antibodies ,EVIDENCE-based medicine ,MEDICAL personnel ,MEDICAL protocols ,GRANULOMATOSIS with polyangiitis ,EXPERTISE ,CHURG-Strauss syndrome ,PROFESSIONAL associations ,IMMUNOSUPPRESSIVE agents ,VASCULITIS ,MICROSCOPIC polyangiitis ,DISEASE remission - Abstract
Objective: To provide evidence‐based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody–associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Methods: Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results: We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low‐quality evidence supporting the recommendations. Conclusion: This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
45. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa.
- Author
-
Chung, Sharon A., Gorelik, Mark, Langford, Carol A., Maz, Mehrdad, Abril, Andy, Guyatt, Gordon, Archer, Amy M., Conn, Doyt L., Full, Kathy A., Grayson, Peter C., Ibarra, Maria F., Imundo, Lisa F., Kim, Susan, Merkel, Peter A., Rhee, Rennie L., Seo, Philip, Stone, John H., Sule, Sangeeta, Sundel, Robert P., and Vitobaldi, Omar I.
- Subjects
THERAPEUTIC use of glucocorticoids ,BIOPSY ,EVIDENCE-based medicine ,POLYARTERITIS nodosa ,QUALITY assurance ,CYCLOPHOSPHAMIDE - Abstract
Objective: To provide evidence‐based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN). Methods: Twenty‐one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for systemic, non–hepatitis B–related PAN. Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results: We present 16 recommendations and 1 ungraded position statement for PAN. Most recommendations were graded as conditional due to the paucity of evidence. These recommendations support early treatment of severe PAN with cyclophosphamide and glucocorticoids, limiting toxicity through minimizing long‐term exposure to both treatments, and the use of imaging and tissue biopsy for disease diagnosis. These recommendations endorse minimizing risk to the patient by using established therapy at disease onset and identify new areas where adjunctive therapy may be warranted. Conclusion: These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with PAN. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
46. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.
- Author
-
Maz, Mehrdad, Chung, Sharon A., Abril, Andy, Langford, Carol A., Gorelik, Mark, Guyatt, Gordon, Archer, Amy M., Conn, Doyt L., Full, Kathy A., Grayson, Peter C., Ibarra, Maria F., Imundo, Lisa F., Kim, Susan, Merkel, Peter A., Rhee, Rennie L., Seo, Philip, Stone, John H., Sule, Sangeeta, Sundel, Robert P., and Vitobaldi, Omar I.
- Subjects
GIANT cell arteritis diagnosis ,UNIVERSITIES & colleges ,CONSENSUS (Social sciences) ,RHEUMATOLOGY ,GIANT cell arteritis ,EVIDENCE-based medicine ,MEDICAL personnel ,VOTING ,TAKAYASU arteritis ,MEDICAL protocols ,RHEUMATOLOGISTS ,PATIENTS' attitudes ,DIAGNOSTIC imaging ,EXPERTISE ,IMMUNOSUPPRESSIVE agents ,DISEASE management - Abstract
Objective: To provide evidence‐based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. Methods: Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. Results: We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid‐sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. Conclusion: These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
47. Comparing Semi-quantitative and Qualitative Methods of Vascular FDG-PET Activity Measurement in Large-Vessel Vasculitis.
- Author
-
Dashora, Himanshu R., Rosenblum, Joel S., Quinn, Kaitlin A., Alessi, Hugh, Novakovich, Elaine, Saboury, Babak, Ahlman, Mark A., and Grayson, Peter C.
- Published
- 2021
- Full Text
- View/download PDF
48. Comparing Semi-quantitative and Qualitative Methods of Vascular FDG-PET Activity Measurement in Large-Vessel Vasculitis.
- Author
-
Dashora, Himanshu R., Rosenblum, Joel S., Quinn, Kaitlin A., Alessi, Hugh, Novakovich, Elaine, Saboury, Babak, Ahlman, Mark A., and Grayson, Peter C.
- Published
- 2021
- Full Text
- View/download PDF
49. Clinical course of 602 patients with Takayasu's arteritis: comparison between Childhood-onset versus adult onset disease.
- Author
-
Danda, Debashish, Goel, Ruchika, Joseph, George, Kumar, Sathish T, Nair, Aswin, Ravindran, Raheesh, Jeyaseelan, L, Merkel, Peter A, and Grayson, Peter C
- Subjects
EVALUATION of medical care ,C-reactive protein ,INFLAMMATION ,RETROSPECTIVE studies ,TAKAYASU arteritis ,COMPARATIVE studies ,DISEASE relapse ,SEVERITY of illness index ,DISEASE duration ,DESCRIPTIVE statistics ,LONGITUDINAL method ,DISEASE remission ,SYMPTOMS ,EVALUATION ,CHILDREN ,ADULTS ,ADOLESCENCE - Abstract
Objectives To describe the clinical profile of Asian Indian patients with Takayasu's arteritis (TAK) and to compare clinical features and outcome of childhood-onset Takayasu's arteritis (cTAK) with adult-onset TAK (aTAK). Methods Data related to clinical features and response to treatment of patients with cTAK (age of onset <16 years) and aTAK from a large observational cohort in our tertiary care teaching hospital were noted and compared. Results Altogether, 602 patients (cTAK = 119; aTAK = 483) were studied. Patients with cTAK had a blunted female: male ratio; but fever, elevated acute phase reactants, involvement of abdominal aorta or its branches, hypertension, abdominal pain, elevated serum creatinine and cardiomyopathy were more common in cTAK as compared with aTAK. Patients with aTAK were more likely to have aortic-arch disease and claudication than cTAK. During follow-up, complete remission was more common in cTAK (87% vs 66%; P < 0.01), but subsequent relapses were equally common (30% vs 27%; P = 0.63). Independent associations of disease duration at presentation with disease extent [Disease Extent Index in TAK (DEI.Tak)] and damage [TAK Damage Score (TADS)] were observed (P ≤ 0.01). Moreover, 54% of patients with symptom duration of >5 years at presentation still continued to have elevated CRP suggesting continued and active inflammation warranting escalation or inititation of immunosuppression. Conclusion Patients with cTAK are more likely to have arterial disease below the diaphragm, systemic inflammation and achieve remission. Disease of the aortic arch is more common in patients with aTAK. Longer duration of symptoms prior to initiation of immunosuppression, thereby leading to extensive disease and damage, reflects ongoing disease activity as the rule rather than exception in untreated TAK. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
50. Effects of the COVID‐19 Pandemic on Patients Living With Vasculitis.
- Author
-
Banerjee, Shubhasree, George, Michael, Young, Kalen, Venkatachalam, Shilpa, Gordon, Jennifer, Burroughs, Cristina, Curtis, David, Ferrada, Marcela, Gavigan, Kelly, Grayson, Peter C., Kullman, Joyce, Danila, Maria I., Curtis, Jeffrey R., Shaw, Dianne G., Benjamin Nowell, W., and Merkel, Peter A.
- Subjects
COVID-19 pandemic ,TELEMEDICINE ,IMMUNOSUPPRESSION ,VASCULITIS ,GLUCOCORTICOIDS ,MEDICAL care - Abstract
Objective: This study aimed to analyze the concerns and health‐related behaviors in patients with vasculitis during the early phase of the coronavirus disease 2019 (COVID‐19) pandemic in North America. Methods: Patients with vasculitis in North America were invited to complete an online survey through the Vasculitis Patient‐Powered Research Network in collaboration with the Vasculitis Foundation and the Relapsing Polychondritis Foundation. Questions focused on concerns and behaviors related to doctors' visits, tests, medication, and telehealth use. Factors affecting their concern and health‐related behaviors were determined. Results: Data from 662 patients were included: 90% of patients were White, 78% were women, 83% expressed moderate or high levels of concern about COVID‐19, and 87% reported that their vasculitis moderately or extremely affected their level of concern. Older age, female sex, lung disease, and immunosuppression were associated with greater concern. Doctors' visits, laboratory tests, and other tests were avoided by 66%, 46%, and 40% of patients, respectively. Younger age, urban location, higher income, higher concern levels, and prednisone use (>10 mg/day) were associated with greater likelihood of avoiding visits or tests. Ten percent of patients on immunosuppressive therapy stopped their medication. Twenty‐nine percent patients on rituximab avoided an infusion. Forty‐four percent of patients had telehealth visits; more visits were reported for younger patients, for patients on glucocorticoids, and in Canada versus the United States. Conclusion: During the COVID‐19 pandemic, patients with vasculitis have high levels of concern and exhibit potentially harmful health‐related behaviors. Health care use varies across different demographic groups and geographic regions. Specific strategies are warranted to facilitate engagement of these patients with the health care system during the pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.